A review study published in The Cochrane Library finds that inhaled epinephrine provides significant relief of croup symptoms in children within 30 minutes compared to placebo. The review included 8 studies involving 225 children. Read the abstract. … [Read more...] about Review study supports inhaled epinephrine for croup
Medical
Positive Phase III results for Teva HFA nasal aerosol
Teva's Qnaze beclomethasone nasal aerosol has met all efficacy endpoints in a Phase III trial. The study involved 470 patients with perennial allergic rhinitis. After 6 weeks of treatment, patients using the product experienced significant reduction in nasal symptoms compared to those using a placebo spray. If approved, Qnaze will be the first non-aqueous intranasal … [Read more...] about Positive Phase III results for Teva HFA nasal aerosol
Successful test of inhaled measles vaccine
An article in the January 31, 2011 issue of PNAS describes how rhesus macaques gained protection against the measles virus after inhalation of a single dose of a dry powder live attenuated measles vaccine (LAMV). Two different DPIs, the PuffHaler and Solovent devices, were shown to be effective methods of delivery for the vaccine. Read the article. … [Read more...] about Successful test of inhaled measles vaccine
US asthma rate continues to increase
According to a new report by the National Center for Health Statistics of the US Center for Disease Control (CDC), the 2009 US asthma rate rose to 8.2% of the population, a historic high. The report includes data from several national surveys. Nearly 96% of patients surveyed reported that they had been taught how to use an inhaler. Read the complete report. … [Read more...] about US asthma rate continues to increase
Positive results for aclidinium alone and in combination with formoterol
Almirall and Forest Laboratories have announced that Phase 3 studies of inhaled aclidinium and Phase 2b studies of an inhaled aclidinium/formoterol combination both met their primary endpoints. As a result, the companies expect to submit regulatory applications for an aclidinium DPI for the treatment of COPD in the US and Europe in mid-2011 and will begin Phase 3 … [Read more...] about Positive results for aclidinium alone and in combination with formoterol
Ritedose recalls albuterol inhalation solution vials in US
Contract manufacturer Ritedose has voluntarily recalled unit dose vials of albuterol inhalation solution due to mislabeling. The single dose vials contain a 2.5 mg/3 mL solution but are labeled as 0.5 mg/3 mL. The product was distributed across the United States and in Puerto Rico. Read the company's press release. … [Read more...] about Ritedose recalls albuterol inhalation solution vials in US
Inspire’s CF drug fails Phase 3 trial
The results from Inspire Pharmaceuticals' second Phase 3 trial of denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis show that the drug failed to meet its primary endpoint, change in FEV from baseline. Denufosol is an ion channel regulator. A previous Phase 3 trial had produced significant change in FEV from baseline, and the company says … [Read more...] about Inspire’s CF drug fails Phase 3 trial
MAP completes final Levadex trial
According to MAP Pharmaceuticals, it has completed a year-long open label safety trial of its Levadex inhaled dihydroergotamine, the final step in its development program for the product. More than 250 patients completed the 12-month study. The company plans to submit an NDA for Levadex in the first half of 2011. Read the company's press release. … [Read more...] about MAP completes final Levadex trial
Pearl announces positive Phase 2b results for COPD drug
According to Pearl Therapeutics, a Phase 2b study has demonstrated that its PT003 glycopyrrolate/formoterol combination MDI provides superior bronchodilation compared to placebo, compared to its individual components, and compared to tiotropium. The trial involved patients with moderate to very severe COPD. Read the company's press release. … [Read more...] about Pearl announces positive Phase 2b results for COPD drug
Verona announces successful proof of concept tests of lead product
Verona Pharma, which has been looking for a partner for its lead product RPL554, an inhaled phosphodiesterase 3 and phosphodiesterase 4 inhibitor for the treatment of asthma, COPD, and allergic rhinitis, announced that it has performed successful delivery tests by nebulizer, MDI, and DPI. Read the company's press release. … [Read more...] about Verona announces successful proof of concept tests of lead product